(Q39880558)

15 September 2017

title

MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy (English)

1 reference

15 September 2017

1 reference

1 reference

1 reference

Todd Boren

1

1 reference

15 September 2017

Yin Xiong

2

1 reference

15 September 2017

Ardeshir Hakam

3

1 reference

15 September 2017

Robert Wenham

4

1 reference

15 September 2017

Sachin Apte

5

1 reference

15 September 2017

Gina Chan

6

1 reference

15 September 2017

Siddharth G Kamath

7

1 reference

15 September 2017

Dung-Tsa Chen

8

1 reference

15 September 2017

Holly Dressman

9

1 reference

15 September 2017

Johnathan M Lancaster

10

1 reference

15 September 2017

language of work or name

English

0 references

publication date

23 February 2009

1 reference

15 September 2017

1 reference

15 September 2017

volume

113

1 reference

15 September 2017

issue

2

1 reference

15 September 2017

page(s)

249-255

1 reference

Response and outcomes in elderly patients with stages IIIC–IV ovarian cancer receiving platinum–taxane chemotherapy

15 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: A Gynecologic Oncology Group Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and Paclitaxel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

Phase II study of gemcitabine in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer--an updated overview

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

MicroRNAs: genomics, biogenesis, mechanism, and function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

Post-transcriptional gene silencing by siRNAs and miRNAs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

Silence from within: endogenous siRNAs and miRNAs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

MicroRNA expression profiles classify human cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

c-Myc-regulated microRNAs modulate E2F1 expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

MicroRNA signatures in human ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

A microRNA expression signature of human solid tumors defines cancer gene targets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

MicroRNAs and their target messenger RNAs associated with endometrial carcinogenesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

MicroRNAs modulate the chemosensitivity of tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

MicroRNA expression profiles for the NCI-60 cancer cell panel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

Acetone extract of Bupleurum scorzonerifolium inhibits proliferation of A549 human lung cancer cells via inducing apoptosis and suppressing telomerase activity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

miRBase: microRNA sequences, targets and gene nomenclature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

Genomic signatures to guide the use of chemotherapeutics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

Breast cancer metastasis: a microRNA story

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

Micro-RNA profiling in kidney and bladder cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

MicroRNA expression profiles in serous ovarian carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

miR-21-mediated tumor growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

Bin1 ablation in mammary gland delays tissue remodeling and drives cancer progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

Overview of microarray analysis of gene expression and its applications to cervical cancer investigation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

Human kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

Accompanying protein alterations in malignant cells with a microtubule-polymerizing drug-resistance phenotype and a primary resistance mechanism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

Kruppel-like factor 5 modulates p53-independent apoptosis through Pim1 survival kinase in cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

Randomized phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.01.014

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YGYNO.2009.01.014

1 reference

15 September 2017

1 reference